Skip to main content

Table 1 Baseline clinical and tumor characteristics

From: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization

Baseline characteristics N (%)/ median (IQR) (N = 166)
Sex (male) 127 (76.5%)
Age (years) 65 (57.75–72)
Etiologies of liver disease
 HBV infection
 HCV infection
 NASH
 Cryptogenic
 Alcohol
 AIH
73 (44.0%)
50 (30.1%)
16 (9.6%)
14 (8.4%)
12 (7.3%)
1 (0.6%)
Cirrhosis 156(94.0%)
 CTP A
  - Score 5
  - Score 6
 CTP B
 -  Score 7
  - Score 8
134 (80.7%)
87 (52.4%)
47 (28.3%)
22 (13.3%)
17 (10.2%)
 5 (3.0%)
MELD score 8.88 (7.69 – 10.43)
Number of HCC
 1
 2–3
  > 3
49 (25.3%)
57 (34.4%)
67 (40.4%)
Location of HCC
 Both lobes
 Right lobe
 Left lobe
76 (45.8%)
75 (45.2%)
15 (9.0%)
Largest tumor diameter (cm)  
  ≤ 3
  > 3—≤ 7
  > 7—≤ 10
  > 10
16 (9.6%)
77 (46.4%)
42 (25.3%)
31 (18.7%)
  1. AIH Autoimmune hepatitis, cm Centimeter, CTP Child-Turcotte-Pugh, HBV Hepatitis B virus, HCC Hepatocellular carcinoma, HCV Hepatitis C virus, IQR Interquartile range, MELD Model for end-stage liver disease, N Number, NASH Non-alcoholic Steatohepatitis, SD Standard deviation